Figure 1. TruGenome^™ CVD test design and reportables.

Test design focused on CVD phenotypes relevant to cardiac clinic patients. Monogenic conditions and risk alleles were evaluated for the strength of evidence for increased disease risk. CVD PRSs and PGx findings were also explored for inclusion. The test includes five components: a 215 gene-disease pair CVD panel, the 35 remaining non-CVD ACMG secondary findings genes, 4 risk alleles or genotypes, PGx findings across 10 gene-drug pairs and a PRS for CAD. Test deliverables include a clinical report for genetic disease and genetic risk findings, an RUO CAD PRS report and a clinical report of pharmacogenomic findings.